This metabolite incorporates a PDE selectivity profile similar to sildenafil and an in vitro potency for PDE5 roughly 50% in the guardian drug. Plasma concentrations of this metabolite are close to 40% of Individuals viewed for sildenafil, so that the metabolite accounts for around 20% of sildenafil's pharmacologic consequences.Pulmonary arterial h